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The cancer anorexia cachexia syndrome is a systemic metabolic
disorder characterized by the catabolism of stored nutrients in
skeletal muscle and adipose tissue that is particularly prevalent in
nonsmall cell lung cancer (NSCLC). Loss of skeletal muscle results
in functional impairments and increased mortality. The aim of the
present study was to characterize the changes in systemic metab-
olism in a genetically engineered mouse model of NSCLC. We
show that a portion of these animals develop loss of skeletal mus-
cle, loss of adipose tissue, and increased inflammatory markers
mirroring the human cachexia syndrome. Using noncachexic and
fasted animals as controls, we report a unique cachexia metabolite
phenotype that includes the loss of peroxisome proliferator-
activated receptor-α (PPARα) -dependent ketone production by
the liver. In this setting, glucocorticoid levels rise and correlate
with skeletal muscle degradation and hepatic markers of gluco-
neogenesis. Restoring ketone production using the PPARα agonist,
fenofibrate, prevents the loss of skeletal muscle mass and body
weight. These results demonstrate how targeting hepatic metab-
olism can prevent muscle wasting in lung cancer, and provide ev-
idence for a therapeutic strategy.
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The cancer anorexia cachexia syndrome (CACS) is a systemicmetabolic disorder characterized by the catabolism of stored
nutrients in muscle and adipose tissue. Clinically, this syndrome
is characterized by loss of body weight, reduced food intake,
increased markers of systemic inflammation, and progressive
functional impairment (1). CACS is particularly prevalent in
patients with nonsmall cell lung cancer (NSCLC), with ∼50%
and 75% with early and advanced-stage disease, respectively,
being affected (2, 3). These patients have increased susceptibility
to chemotherapeutic toxicity, poor quality of life scores, worse
response to chemotherapy, and increased mortality (4–6).
Much of the negative impact of CACS is thought to be the
result of the reduction in skeletal muscle mass and, more spe-
cifically, a preferential loss of the muscle used to generate power
(type II myofibers) compared with muscle used for stability (type
I myofibers) (7–9). The systemic signals leading to skeletal
muscle destruction in cancer are unknown; however, several
mechanisms have been proposed, including tumor-released fac-
tors (10, 11), tumor-induced changes to the stromal environment
(12), up-regulation of inflammatory cytokines (13–15), and
hormonal dysregulation (16).
One class of hormones that plays an important role in the
regulation of skeletal muscle mass during times of illness is
glucocorticoids (17, 18). In patients with NSCLC, the level and
circadian pattern of serum glucocorticoids are significantly al-
tered (19–26). Glucocorticoids induce skeletal muscle degrada-
tion by enhancing the expression of genes that reduce protein
synthesis and enhance protein degradation via the glucocorticoid
receptor (27–30). For example, the binding of glucocorticoids to
the glucocorticoid receptor leads to increased expression of
Ddit4, which is known to reduce mammalian target of rapamycin
complex 1 (mTORC1) activity (31–34), and increased expression
of the E3 ligases, Fbxo32 and Trim63, which bind to sarcomeric
proteins and mediate breakdown of the myofibrils via the
ubiquitin-proteasome system (35–39).
Therapeutic strategies that target skeletal muscle loss have
been grossly unsuccessful and, despite over 60 y of investigation,
there continues to be no effective treatment for CACS (40).
These failures suggest that the loss of skeletal muscle mass in
CACS is secondary to a more global alteration in systemic me-
tabolism. One important confounder that limits the identifica-
tion of specific signals that induce CACS is anorexia. A
reduction in food intake is an important contributor to changes
in body composition including skeletal muscle loss. In fact, both
fasting and CACS induce a common degradation program that
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includes the aforementioned E3 ligases and the ubiquitin-
proteasome system (41). Therefore, the contribution of an-
orexia to altered systemic metabolism must be taken into
account in CACS models (42).
KRAS, LKB1, EGFR, and TP53 are the most frequently mu-
tated genes in human NSCLC (43). Two important risk factors
for developing CACS are (i) the presence of a KRAS mutation
and (ii) the presence and burden of metastasis (44); however,
genetically engineered mice with a Kras mutation (G12D) alone
do not promptly develop CACS or metastasis (45). When Lkb1
deficiency is introduced to Kras-mutated tumors, an aggressive,
metastatic phenotype arises, and we hypothesized that this
combination of mutations would recapitulate the human CACS
syndrome in mice (46, 47).
The aim of the present study was to assess the changes in
systemic metabolism in an inducible, genetically engineered
mouse model of NSCLC. We show that a portion of these ani-
mals develop the human CACS syndrome, including: loss of
skeletal muscle (type II myofiber atrophy), loss of adipose tissue,
decreased food intake, and increased inflammatory markers.
Using tissues from noncachexic and fasted animals as controls,
we report a unique CACS gene and metabolite signature that
included the loss of peroxisome proliferator-activated receptor-α
(PPARα) -dependent ketone production in the liver. In this
setting, glucocorticoid levels rise and correlate with degradation
of type II muscle fibers and markers of hepatic gluconeogenesis.
This process could be stopped by restoring ketone production
using the PPARα agonist, fenofibrate, which prevented weight
loss and protected mice from the loss of skeletal muscle mass.
These results demonstrate how targeting the hepatic metabolism
can prevent muscle wasting in lung cancer.
Results
A Subset of Mice with NSCLC Develop Cachexia. Given the aggres-
sive tumor phenotype and potential for metastasis, we hypothe-
sized that KrasG12D/+;Lkb1f/f (KL) mice would develop CACS.
Tumors were induced in the lungs of adult KL mice via in-
tranasal administration of adenovirus-containing Cre recombi-
nase (Cre), as previously described (46). Using a clinically
relevant threshold for moderate weight loss, CACS was a priori-
defined as a loss of 10% or more of body weight from the peak
weight obtained during the study (48). Body weight was mea-
sured weekly in a cohort of mice induced with Cre or control
mice treated with an empty adenovirus vector (Empty). Sixty-
percent (12 of 20) of mice treated with Cre developed CACS,
while the other 40% and the Empty-treated mice maintained
their body weight over the duration of the study (Fig. 1A). The
divergence in the Cre-treated population occurred about 6 wk
following treatment and was associated with a reduction in food
intake compared with the Empty-treated mice (Fig. 1B). The loss
of body weight included a reduction in skeletal muscle, as
demonstrated by significant decrease in gastrocnemius mass (Fig.
1C), and white adipose tissue (WAT), as demonstrated by a
significant decrease in the mass of the gonadal fat pad (Fig. 1D)
compared with Empty-treated mice. Liver mass was significantly
reduced in both non-CACS tumor-bearing mice and CACS
compared with Empty-treated mice (Fig. 1E), whereas kidney
mass was unchanged (Fig. 1F).
Cachexia Does Not Correlate with Tumor Burden or Subtype of Lung
Cancer. KL mice develop aggressive, metastatic tumors with ei-
ther an adenocarcinoma or squamous cell phenotype similar to
human NSCLC (46, 49). To determine if CACS mice featured a
predominant tumor type or a greater degree of tumor burden, we
histologically examined lung tumors from non-CACS and CACS
mice (Fig. 2 and Table S1). Overall, we detected several subtypes
of adenocarcinoma (acinar, mucinous, and papillary) and ade-
nocarcinoma in situ (lepidic, mucinous, and papillary), with no
evidence of squamous cell carcinoma. Mice with CACS tended
to have more tumor with an acinar subtype of adenocarcinoma.
We observed lymph node metastasis in four mice, all of which
had CACS (Fig. 2A and Table S1). No brain or lymph node
metastasis were observed grossly. The degree of tumor burden,
as measured by the percent of lung occupied by tumor, did not
correlate significantly with the degree of weight loss (Fig. 2B).
Cachexic Mice Have a Unique Serum Metabolite Profile Characterized
by Hypoketonemia. To assess for changes in systemic metabolism
that could account for CACS development, we measured serum
metabolites, hormones, and cytokines involved in nutrient ho-
meostasis in tumor-bearing mice (Fig. 3 and Fig. S1). Because of
the significant overlap of shared features between CACS and
anorexia, we included a cohort of nontumor-bearing fed and
fasted mice. In comparison with fed mice, fasted mice had re-
duced serum glucose (89 ± 4 vs. 167 ± 6 mg/dL, P < 0.001),
increased β-hydroxybutyrate (BHB) (0.69 ± 0.19 vs. 0.09 ±
0.02 mM, P < 0.05), and increased nonesterified fatty acids
(NEFA) (1.66 ± 0.10 vs. 0.36 ± 0.05 mEq/L, P < 0.001), all of
which are expected following fasting. There was a trend toward
an increase in serum triglycerides (TG) (155.1 ± 23 vs. 101.8 ±
17.7 mg/dL, P = 0.10) in fasted mice. Interestingly, the most
severely CACS mice (weight loss more than 15%) displayed a
unique metabolic phenotype consisting of low glucose (88 ± 7 vs.
138 ± 8 mg/dL, P < 0.001), high NEFA (2.19 ± 0.40 vs. 1.30 ±
0.06 mEq/L, P < 0.05), and very low BHB (0.09 ± 0.04 vs. 0.37 ±
0.05 mM, P < 0.01) compared with non-CACS mice. Acetoacetate,
another ketone body produced by the liver, could not be detected in
the serum of any mice. Levels of serum lactate, insulin, insulin-like
growth factor-1 (IGF1), and insulin-like growth factor binding
protein-3 (IGFBP3) were not significantly different in CACS vs.
non-CACS mice (Fig. S1). Three of the CACS mice had detectable
IL-6 in the serum (∼15 pg/mL), while IL-6 was not detectable in the
serum of the non-CACS mice (Fig. S1). Corticosterone levels were
similar between CACS and non-CACS mice until 6 wk following
Fig. 1. Cachexia development in genetically induced lung cancer. (A) Weight
normalized to peak weight over time following induction of lung cancer using
adenovirus to deliver Cre recombinase (Cre, red boxes) and control mice
treated with an empty adenovirus (Empty, black triangles, n = 6). Following
Cre treatment, n = 12 mice developed cachexia (+cacs) and n = 8 mice main-
tained their weight (−cacs). (B) Food intake in mice from A treated with Empty
or Cre virus. (C) Gastrocnemius (Gastroc) weight in Empty, Cre−cacs, and Cre+
cacs mice. (D) Gonadal WAT weight in Empty, Cre−cacs, and Cre+cacs mice.
(E) Liver weight in Empty, Cre −cacs, and Cre +cacs mice. (F) Kidney weight in
Empty, Cre −cacs, and Cre +cacs mice. Bar graphs are mean ± SEM. Student’s
t test comparisons with the Empty group. *P < 0.05.
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Cre administration when the levels increased in CACS mice but not
in non-CACS mice (Fig. 3B).
Cachexic Mice Have Reduced Hepatic Fatty Acid Oxidative Capacity
and Increased Markers of Gluconeogenesis. Ketones are an impor-
tant source of energy for peripheral tissues in times of carbohy-
drate deficiency. The liver produces ketones using the oxidation of
NEFA to generate Acetyl CoA. Acetyl CoA then undergoes two
condensation reactions to form β-hydroxy-β-methylglutaryl-CoA
(HMG-CoA) by the enzyme, HMGCS2. HMG-CoA can then
be cleaved to generate acetoacetate or cleaved and reduced to
produce BHB by BDH1. Acetyl CoA is diverted away from
HMGCS2 to enter the TCA cycle when sufficient oxaloacetate
(OAA) is available and citrate synthase is active. Therefore, one
potential cause of hypoketonemia in CACS mice could be an in-
crease in hepatic OAA content or production.
Glycogen is a major contributor to hepatic OAA, so we
measured glycogen content in the livers of fed, fasted, and
tumor-bearing mice. Compared with fed mice, glycogen content
was reduced in tumor-bearing and fasted mice to a similar de-
gree (Fig. 4A). Because glycogen is not the sole contributor to
OAA levels, we directly measured glycolytic and TCA cycle
metabolites from liver tissue, including pyruvate, OAA, and
citrate. Surprisingly, the relative amount of OAA in livers from
CACS mice was significantly lower than non-CACS mice,
thereby favoring the diversion of Acetyl CoA to ketogenesis (Fig.
4B). The level of citrate was similar in all groups, suggesting
normal citrate synthase activity in CACS mice. Consistent with
our findings from the serum, the 16 and 18 carbon saturated fatty
acids, palmitate and stearate, were significantly increased in the
livers of CACS mice, whereas BHB was significantly reduced in
comparison with non-CACS mice. Interestingly, the abundance
of BHB from the livers of fasted mice was also reduced in
comparison with non-CACS mice. When measured in the gas-
trocnemius, however, fasted mice had a dramatic increase in
BHB content, suggesting the liver rapidly secretes ketones after
they are formed in the fasted state.
Another potential cause for hypoketonemia in CACS mice is a
reduction in the oxidation of NEFA. AMPK can regulate fatty
acid oxidation by phosphorylating and inhibiting Acetyl CoA
carboxylase (ACC). Consequently, Malonyl CoA levels fall,
which relieves the negative inhibition on NEFA entry into the
mitochondria via CPT1. We probed hepatic liver lysates from
nontumor-bearing fed and fasted mice in comparison with tumor
bearing non-CACS and CACS mice for evidence of AMPK ac-
tivation (Fig. S2). The level of serine 79 phosphorylation of ACC
in CACS was unchanged when normalized for total ACC
abundance (phospho/total) compared with non-CACS livers.
Regarding AMPK itself, the phospho/total ratio of threonine
172 was significantly reduced in CACS compared with non-
CACS, an effect mostly driven by a decreased amount of total
AMPK in non-CACS lysates. Two other AMPK targets, Raptor
and ULK1, were also altered in our samples. The phospho/total
ratio of Raptor was increased in non-CACS liver lysates, whereas
phosphorylation of ULK1 was unchanged. Additionally, the total
protein content of both Raptor and ULK1 were significantly
reduced in CACS compared with the non-CACS state.
Because of the significant differences in protein abundance
between non-CACS and CACS livers, we decided to more
globally assess changes in metabolism at the enzymatic level by
performing RNA-Seq on livers from non-CACS, CACS, and
fasted mice. At a whole-transcriptome level, mice from each
group clustered together in an unbiased principal component
analysis (Fig. S3A). A pathway enrichment analysis using the
differentially expressed genes among the three groups identified
the following Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways as down-regulated in CACS: peroxisome, the
PPAR signaling pathway, and fatty acid metabolism. We
reviewed the gene expression of the β-oxidation pathway and
noticed several PPARα target genes were reduced in CACS
mice, including Acox1, the first and rate-limiting enzyme of the
peroxisomal β-oxidation pathway, and the key genes involved in
ketogenesis, Hmgcs2 and Bdh1 (Fig. S3B). We measured the
protein products of these genes by Western blot and confirmed a
reduction in Acox1 abundance (Fig. 4 C and D). Protein levels of
HMGCS2 and BDH1, however, were not decreased.
To function as a transcription factor, PPARα must translocate
into the nucleus where it can associate with the transcription
apparatus (50). We measured the abundance of PPARα protein
in nuclear and cytoplasmic liver fractions by immunoprecipita-
tion (Fig. 4E and Fig. S3 C and D). Mice without CACS dis-
played high levels of nuclear PPARα in comparison with fed,
fasted, and fenofibrate- (a PPARα agonist) treated mice. In
CACS livers, PPARα level was reduced in both the nucleus and
cytoplasm in comparison with non-CACS mice.
The following KEGG pathways were up-regulated in the livers
of CACS mice: ribosome, arginine biosynthesis, and glucagon
Fig. 2. Cachexia does not correlate with tumor burden or subtype of lung
cancer. (A) Normal lung (Top, Left), adenocarcinoma subtypes identified
histologically: papillary (Top, Right), acinar (Middle, Left), mucinous (Middle,
Right), lymph node metastasis containing acinar adenocarcinoma (Bottom,
Left), and lepidic subtype of adenocarcinoma in situ (Bottom, Right). (Scale
bars: Right Top, Middle, and Bottom and Left Middle, 50 μm; Left Top and
Bottom, 100 μm.) (B) Percent of total weight loss over the duration of the
study vs. tumor burden, as defined by the percent of lung replaced by tumor
in mice with (Cre +cacs, red circles) or without (Cre −cacs, black circles). Linear
regression analysis (R2, coefficient of determination, and p, P value).
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signaling pathway. We noticed that the glucagon signaling
pathway contained the gene, Pck1, which is the major regulatory
point for gluconeogenesis, so we searched our dataset for other
differentially expressed genes capable of generated gluconeo-
genic precursors. Remarkably, many genes involved in the con-
version of amino acids into pyruvate were increased in CACS
livers (Fig. 4 F and G and Fig. S3F). This finding is in agreement
with the increase in pyruvate (Fig. 4B) and the metabolites of
upper glycolysis (Fig. S3 G and H) identified in the metabolomic
analysis. All of these results suggest that PPARα-dependent fatty
acid oxidation is impaired and gluconeogenesis is enhanced in
the liver of CACS mice compared with non-CACS mice.
BHB is an endogenous inhibitor of histone deacetylases
(HDACs) (51, 52). Therefore, some of the changes in gene ex-
pression observed in the livers of CACS mice could be explained
by altered histone acetylation. We measured the level of acety-
lated (Lys9/Lys14) histone H3 in the livers of fed, fasted, and
tumor-bearing mice and observed a significant reduction in
acetylation in CACS mice (Fig. S3E).
Cachexic Muscle Has Reduced Type II Myofiber Size, Reduced mTORC1
Activity, and Altered Amino Acid Content. Skeletal muscle is a
reservoir for amino acids that the liver can use to replete the
TCA cycle and serve as gluconeogenic substrates in times of car-
bohydrate deficiency (53). This effect is driven by glucocorticoid-
dependent degradation of type II myofibers (27, 29). Given that
the CACS mice in our model have increased corticosterone levels
and evidence of increased gluconeogenic capacity in the liver, we
interrogated changes in skeletal muscle fiber type using the ex-
tensor digitorum longus (EDL) and the soleus as examples of type
II and type I myofiber-containing muscles. EDL mass was signif-
icantly reduced in CACS mice, whereas the mass of the soleus was
unchanged (Fig. 5A). We measured the cross sectional area (CSA)
of each fiber type using antibodies against specific myosin heavy
chain isoforms (Fig. 5B) (54). In the EDL and, to a lesser extent,
the soleus, we detected a shift toward smaller myofiber CSA (Fig.
5C). Type I and type IIa myofibers from CACS mice were similar
in size compared with non-CACS in the EDL and soleus (Fig. 5 D
and E); however, the CSA of type IIx and IIb myofibers were
dramatically reduced (Fig. 5E).
We performed RNA-Seq in the gastrocnemius muscle from
non-CACS, CACS, and fasted mice to identify gene-expression
patterns that would explain the loss of type IIx and IIb myofibers.
Like the liver, the overall skeletal muscle expression pattern was
very consistent among animals from the same condition, with
striking differences between groups following unbiased clustering
(Fig. 6A). There was a noteworthy overlap between the differ-
entially up-regulated genes in CACS and fasted muscle (Fig. 6B
and Dataset S1). This intersection of CACS and fasted muscle
included the E3 ligases, Fbxo32 and Trim63, which are known
mediators of muscle breakdown in the setting of cancer and
fasting (41). The genes up-regulated only in fasted muscle in-
cluded the KEGG pathways: fatty acid degradation, the PPAR
signaling pathway, and peroxisome. The genes specifically up-
regulated in CACS muscle included the KEGG pathways: pro-
teasome, mTOR signaling pathway, and lysosome. Specifically,
the glucocorticoid-regulated mTOR inhibitor Ddit4, the regula-
tory subunit of phosphoinositide-3 kinase Pik3r1, and the main
transcriptional target of the insulin signaling cascade, Foxo1,
were differentially increased in only CACS muscle. We validated
some of these gene-expression changes using qPCR (Fig. 6C).
In accordance with the changes at the level of mRNA ex-
pression, we detected significant differences in the abundance of
signaling proteins in CACS skeletal muscle. The Pik3r1 protein
product, p85, was increased in comparison with non-CACS tissue
(Fig. 6D and Fig. S4). Also, in agreement with an increased ex-
pression of Ddit4 and Sesn1, phosphoprotein markers of mTORC1
and S6K activity were reduced, including phosphorylation of serine
235/6 of S6, serine 757 of ULK1, and threonine 37 of 46 of 4E-
BP1. This reduction in mTORC1 activity was associated with sig-
nificant differences in amino acid abundance in the gastrocnemius
(Fig. 6E). Gluconeogenic amino acids, such as alanine and glycine,
were significantly reduced in CACS compared with non-CACS
muscle. Conversely, the branched chain amino acids (BCAAs)
and amino acids with either basic or acidic side chains were in-
creased. These results are consistent with a model in which glu-
cocorticoids induce the expression of mTORC1 inhibitors, which
promote muscle degradation.
Fig. 3. Changes in serum metabolites and hormones in mice with and
without cachexia. (A) Percent weight loss, serum glucose, BHB, NEFA, and TG
in fed (Fed) and fasted (Fast) nontumor-bearing mice and tumor-bearing
(Cre) mice. Values in each column are color-coded in a red (highest) to
blue (lowest) heatmap. (B) Serum corticosterone (mean ± SEM) levels over
time following induction of lung cancer in noncachexic (Cre −cacs, red open
boxes, n = 5) and cachexic (Cre +cacs, red closed boxes, n = 12).
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The PPARα Agonist, Fenofibrate, Restores Ketogenesis and Prevents
Skeletal Muscle Loss in Tumor Bearing Animals. CACS mice display a
hypoketonemic phenotype that is associated with a reduction in
hepatic fatty acid oxidation genes (e.g., Acox1) that are known to be
regulated by PPARα. We hypothesized that treatment with a
PPARα agonist would restore hepatic ketogenesis, prevent the
reliance on hepatic gluconeogenesis, and thereby avert the need to
degrade type II myofibers for amino acids. Mice were started on a
0.2% fenofibrate (Feno) diet 6 wk following the induction of
NSCLC and changes in body weight and food intake were mea-
sured. Relative body weight was unchanged in mice treated with
Cre compared with a cohort of nontumor bearing mice on the Feno
diet (Fig. 7A). Food intake tended to be lower in tumor-bearing
mice; however, this difference was not statistically significant (Fig.
7B). Tissues were harvested at 11 wk following induction and there
was no difference in tumor burden in Cre treated mice on Feno
compared with tumor-bearing mice on a normal chow diet.
The Feno diet induced an up-regulation in five of seven
PPARα target genes we interrogated (Hmgcs2, Acadm, Cyp4a14,
Acox1, Ehhadh, but not Cpt1a and Bdh1) in the livers of
nontumor-bearing mice compared with mice on a normal chow
diet (Fig. 7C). Tumor-bearing mice on a normal chow diet had
reduced expression of Bdh1, Acox1, and Ehhadh compared with
nontumor-bearing mice. The expression of Hmgcs2, Acadm, Cpt1a,
Cyp4a14, Acox1, and Ehhadh were significantly increased in tumor-
bearing mice on the Feno diet compared with Cre-treated mice on a
normal chow diet. These changes in hepatic gene expression pro-
tected against the CACS serum profile we identified earlier. Serum
BHB was increased in both nontumor-bearing and Cre-treated mice
on Feno, and serum NEFA in Cre-treated animals was reduced to
the level found in nontumor-bearing mice (Fig. 7D). Importantly,
the restoration of ketogenesis with Feno was associated with re-
duced corticosterone levels (Fig. 7E), preserved gastrocnemius mass
(Fig. 7F), increased liver mass, and showed a modest improvement
in WAT mass (Fig. 7G). The mass of the EDL (which contains type
IIb and IIx fibers) but not the mass of the soleus (mainly I and IIa
fibers) was increased with Feno treatment in comparison with
tumor-bearing mice on a normal chow (Fig. S4A).
We conducted a subanalysis comparing tumor-bearing mice
on normal chow and Feno that lost similar amounts of weight
Fig. 4. Changes in liver metabolites and gene ex-
pression in fasted and tumor-bearing mice. (A) Liver
glycogen content in fed (Fed) and fasted (Fasted)
nontumor-bearing mice and tumor-bearing mice
with (+cacs) and without (−cacs) cachexia. (B) Pyru-
vate, OAA, citrate, palmitate (C16:0), stearate
(C18:0), and BHB metabolite abundance relative
to noncacs liver and gastrocnemius (Gastroc). n =
5 each. (C) Immunoblot of liver lysates for indicated
proteins. (D) Normalized quantitation of ACOX1 in-
tensity over β-actin intensity from the immunoblot in
D normalized to the average value from the −cacs
group. (E) PPARα immunoprecipitation from hepatic
nuclear (Nuc) and cytoplasmic (Cyto) fractions taken
from Fed, Fasted, fenofibrate (Feno)-treated, and
tumor-bearing mice −cacs and +cacs. (F) FPKM from
RNA-Seq for indicated genes in −cacs, +cacs, and
Fasted mice. Box and whiskers plot with minimum
and maximum whiskers. (G) Schematic view of py-
ruvate generated from different amino acids using
genes from F. Red color denotes up-regulated genes.
Bar graphs are mean ± SEM. Student’s t test com-
pared with Fed mice in A and to −cacs in B, D, and E.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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(Fig. S4 B–I). In this analysis of primarily non-CACS mice, Feno
induced a large increase in liver weight and a significant reduction
in serum NEFA. Other serum metabolites (glucose, BHB) and
tissue weights (gastrocnemius, WAT, and kidney) were unchanged.
Discussion
In this study we used a genetically engineered mouse model of
NSCLC along with fasted animals as controls to characterize the
changes in intermediary metabolism that occur with CACS. We
identified a unique metabolic phenotype in CACS animals
characterized by low serum glucose, increased NEFA, and re-
duced BHB. Using traditional biochemical assays, targeted me-
tabolite profiling, and RNA-Seq in the liver and skeletal muscle,
we have shown that the loss of serum ketones is the result of a
rewired hepatic metabolism favoring gluconeogenesis and sup-
pressing expression of PPARα target genes involved in fatty acid
oxidation. This rewiring was associated with a rise in serum
glucocorticoids, which degrades type II muscle fibers to provide
amino acid substrate to the liver for glucose production. Treating
with fenofibrate induced hepatic proliferation, restored PPARα-
dependent gene expression, reversed the CACS metabolic phe-
notype, and prevented skeletal muscle wasting (Fig. 7H).
KL mice are an ideal preclinical model to study CACS. Fol-
lowing induction, this model accumulates significant tumor
burden and lymph node metastasis in a convenient time frame.
We found that 60% of tumor-bearing KL mice developed CACS.
This finding is similar in magnitude to the incidence of CACS in
humans with NSCLC (50–75%), but it may be an overestimate of
true CACS from a metabolic point of view (2, 3). Despite our a
priori definition of CACS as 10% weight loss, we only detected a
distinct metabolic phenotype in tumor bearing mice that lost
over 15% of peak body weight. Therefore, future studies should
use this higher, experimentally determined cut-off value.
The liver is a critical regulator of whole-body glucose and lipid
metabolism. In this study, we determined that CACS mice have
reduced ketogenesis due to a reduction in PPARα-dependent
gene expression that can be overcome using the PPARα agonist,
fenofibrate. Fenofibrate modulates the expression of PPARα
target genes involved in lipoprotein and fatty acid metabolism in
the liver, thereby reducing the availability of NEFA for TG
synthesis and export. The resulting clinical effect is a modest
reduction in serum TG and TG-rich lipoproteins for which it has
received Food and Drug Administration approval (55). We
predict that other strategies to induce PPARα signaling would
protect against muscle loss in tumor-bearing animals. For ex-
ample, consumption of the n-3 polyunsaturated fatty acids,
eicosapentaenoic acid and docosahexaenoic acid, induce the
expression of PPARα targets genes, such as Acox1 (56). This
finding, in combination with our present results, may explain the
potential benefit of omega-3 supplements in CACS (57).
Our work complements the findings of Masri et al. (58), which
identified the unexpected role of lung adenocarcinoma as a
potent organizer of the hepatic circadian rhythm, including
changes to both gluconeogenesis and lipid metabolism. One
potential contributor to these changes in gene expression is a loss
of hepatic BHB, which is an endogenous inhibitor of HDACs
(51, 52). The loss of BHB production is expected to increase
HDAC function and reduce histone acetylation. In support of
this theory, we show that CACS mice have reduced levels of
histone H3 acetylation in the liver. Future studies should focus
on the role of epigenetic changes, including histone acetylation
at the promoters of gluconeogenic genes and PPARα targets.
In agreement with our findings, Flint et al. (59) recently
identified reduced ketogenesis in both the C26 allograft CACS
model and the KPC (KrasG12D/+; Trp53R172H/+; Pdx-1-Cre/+)
genetically engineered mouse model of pancreatic ductal ade-
nocarcinoma, suggesting that the hypoketonemic phenotype is im-
portant in other CACS-related cancer types. In their model, IL-6 is a
necessary and sufficient upstream signal that reduces PPARα-
dependent hepatic ketogenesis (59). In our study, however, the serum
levels of IL-6 were only detectable in 3 of 20 tumor-bearing mice and
at levels over 10-fold lower than those found in C26 or KPC mice
(59), suggesting that other factors may be contributing to the sup-
pression of PPARα. Interestingly, IL-6 can stimulate hypothalamic
release of corticotropin-releasing hormone, which may drive exces-
sive glucocorticoid production and modulate the interaction between
hepatic PPARα and the glucocorticoid receptor (18).
Fig. 5. Cachexia promotes Type IIx/b myofiber atrophy. (A) EDL and soleus
muscle weight in nontumor-bearing fed and fasted mice in comparison with
tumor-bearing mice with (+cacs) and without (−cacs) cachexia. (B) Representa-
tive photomicrograph of skeletal muscle cross-section following myosin heavy-
chain fiber typing using immunofluorescence on EDL (Left) and soleus (Right).
Cy5 (pink, type I), GFP (green, type IIA), unstained (black, type IIx), and dsRed
(red, type IIB). (Scale bar, 320 μm.) (C) Type I and (D) type IIA myofiber CSA from
noncachexic (black, −cacs) and cachexic (red, +cacs) EDL (Left) and soleus (Right)
muscles. (E) Type IIx (Left) and type IIb (Right) EDL myofiber CSA from non-
cachexic (black, −cacs) and cachexic (red, +cacs) mice. Myofiber CSA from n =
3 mice were pooled to obtain data for C–E. Mean ± SEM indicated in each plot.
Student’s t test comparing −cacs and +cacs groups, *P < 0.05, ****P < 0.0001.
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The upstream regulators of PPARα in our CACS model are
under active investigation. PPARα can modulate gene expres-
sion together with coactivators (e.g., PGC-1α and RXR), core-
pressors (e.g., NCoR1 and SMRT), or other nuclear receptors,
including the glucocorticoid receptor (60). Each of these nuclear
receptors can be regulated at the level of protein abundance,
agonist binding, or posttranslational modifications (e.g., phos-
phorylation or glycosylation), which increases the complexity of
the signaling network. We speculate that, in CACS, total PPARα
protein level is being reduced by a posttranslational modification
because the amount of Pparamessage in the RNA-Seq analysis is
not significantly different from non-CACS mice.
Our data suggest that the loss of skeletal muscle during CACS is a
by-product of increased hepatic gluconeogenesis that is driven, at
least in part, by glucocorticoids. This finding is in agreement with
other mouse models of cancer, where glucocorticoids and gluconeo-
genesis are increased (12, 28, 58, 59, 61, 62), and in agreement with
findings from humans with NSCLC that have changes in the level and
circadian pattern of serum glucocorticoids (19–26). In our model, the
rise in glucocorticoids occurred in tandem with a reduction in food
intake. Interestingly, restoring serum ketones with fenofibrate treat-
ment reduces glucocorticoid levels despite a persistent decrease in
food intake. Because the hypothalamus can metabolize and respond
to ketone bodies (63, 64), it is possible that the ketone bodies can
directly alter the hypothalamus–pituitary–adrenal axis.
In KL mice with CACS, we found evidence of a glucocorticoid-
dependent reduction in skeletal muscle protein synthesis includ-
ing up-regulation of the gene, Ddit4, which is known to reduce
mTORC1 activity (31, 32). Furthermore, we found evidence for
increased expression of proteasome and lysosome genes that cor-
related with elevated BCAAs. BCAAs are also elevated in the serum
of mice and humans with pancreatic adenocarcinoma, which is likely
the consequence of glucocorticoid-dependent type II myofiber deg-
radation (59, 65). These BCAAs can be used by the Kras mutant
lung tumor for protein synthesis or as a source of exogenous nitrogen
(66). In rodents, supplementation with BCAAs minimizes muscle
loss; however, this finding is less clear in humans because of high
rates of attrition during clinical trials (67). Our results support the
hypothesis that lung tumors alter systemic metabolism to gain access
to endogenous growth substrates, such as BCAAs.
This study quantified the metabolic alterations following the
induction of lung cancer in a genetically engineered mouse model.
We identified a unique combination of serum metabolites that can
be used to identify animals with CACS. Using large-scale profil-
ing techniques, we identified deficits in PPARα-dependent gene
expression and showed that the PPARα activator, fenofibrate,
prevents the development of CACS in mice. This protection is
likely related to an enhancement in peroxisome proliferator activity
in the liver resulting in improved fatty acid oxidation. These un-
expected results suggest that activation of fatty acid oxidation and
ketogenesis in the liver is likely to be more effective as a therapy for
CACS than targeting protein metabolism in skeletal muscle.
We acknowledge that this study is limited because the results
are based on a single genetically engineered mouse model and our
findings need to be validated across multiple tumor types and
distinct oncogenic drivers. Additionally, we are eager to confirm
Fig. 6. Changes in skeletal muscle metabolites and
gene expression in fasted and tumor-bearing mice.
(A) Unbiased clustering of RNA-Seq using gastroc-
nemius from nontumor-bearing fasted mice com-
pared with tumor-bearing cachexic (+cacs) and
noncachexic (−cacs) mice. n = 5 each. (B) Venn dia-
gram displaying the proportion and examples of
differentially expressed genes in +cacs samples
alone, fasted samples alone, and genes contained in
both conditions. (C) Relative expression of −cacs,
+cacs, and fasted gastrocnemius mRNA using qPCR
normalized to the average value from the −cacs
group. n = 5. (D) Immunoblot of tibialis anterior ly-
sates for indicated proteins. (E) Relative abundance
of amino acids in gastrocnemius muscles from
+cacs, −cacs, and fasted mice normalized to the av-
erage value from the −cacs group. Bar graphs are
mean ± SEM. Student’s t test comparing +cacs to
−cacs mice. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.
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the relevance of our findings in samples from patients with met-
astatic KRAS-mutant lung cancer with or without CACS.
Methods
Animal Care and Tumor Induction. KrasG12D/+;Lkb1f/f mice have been pre-
viously described (46). Mice were housed in a 12-h light/dark cycle and 22 °C
ambient temperature, and received rodent chow (PicoLab Rodent 20 5053;
Lab Diet) with or without fenofibrate [0.2% (wt/wt)] (68) and free access to
drinking water. Adenovirus CMV-Cre (Ad5CMV-Cre) and Empty vector con-
trol were purchased from the University of Iowa Gene Transfer Vector Core
(Iowa City, IA). Tumors were induced in adult (12- to 20-wk-old) male mice
via intranasal administration of 75 μL of PBS containing 2.5 × 107 pfu of
adenovirus and 1 mM CaCl2.
Tissue Collection. Before tissues and serum collection, mice were food-
deprived for 3 h in tumor-bearing mice, 18 h in fasted mice, and fasted
overnight (roughly 15 h) and then allowed free access to food for 4 h in fed
mice. Tail glucose was measured using a glucose meter (Ascensia) before CO2
asphyxiation. Immediately following killing, whole blood was collected via
cardiac puncture and placed immediately on ice. Next, the whole liver was
Fig. 7. Fenofibrate treatment prevents cachexia in tumor-bearing mice. (A) Weight normalized to peak weight over time following induction of lung cancer using
adenovirus to deliver Cre recombinase in mice fed dietary fenofibrate (Cre+feno, orange open diamonds, n = 7) starting at 6.5 wk (black arrow) compared with Cre-
treated (Cre) mice fed normal chow (n = 20) and nontumor bearingmice fed dietary fenofibrate (Fed+feno, blue closed diamonds, n = 4). (B) Food intake in mice from
A. Red boxes represent Cre data reproduced from Fig. 1B. (C) Relative expression of PPARα target genes using qPCR from livers of nontumor-bearing (Fed, black bars,
n = 5) and tumor bearing (Cre, n = 10) mice on a normal chow diet compared with nontumor bearing (Fed+feno, blue bars, n = 3) and tumor-bearing (Cre+feno,
orange bars, n = 7) mice fed dietary fenofibrate (feno). (D) Serum BHB (Left) and NEFA (Right) from mice described in C. (E) Serum corticosterone levels over time
following induction of lung cancer in nontumor-bearing (Fed+feno, blue diamonds, n = 4) and tumor-bearing (Cre+feno, orange diamonds, n = 7) mice fed dietary
fenofibrate starting at 6.5 wk. (F) Gastrocnemius (Gastroc) weight from nontumor-bearing (Fed, black triangles, n = 5) and tumor bearing (Cre, red boxes, n = 16) mice
on a normal chow diet compared with nontumor-bearing (Fed+feno, blue diamonds, n = 3) and tumor-bearing (Cre+feno, orange diamonds, n = 7) mice fed dietary
fenofibrate (feno). (G) Gonadal WAT from mice described in F. (H) Changes in intermediary metabolism following onset of cachexia: excess lipolysis in adipose tissue
increases serum NEFA, which can be used by the liver and skeletal muscle. Defects in hepatic ketogenesis reduce serum ketone levels resulting in excess glucocorticoid
production. Glucocorticoids modulate hepatic metabolism and induce skeletal muscle degradation to enhance gluconeogenesis. Fenofibrate restores hepatic keto-
genesis and reduces serum glucocorticoids thereby preventing skeletal muscle degradation. Bar graphs are mean± SEM. Student’s t test compared with Fedmice: *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Student’s t test compared with Cre mice: #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001.
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removed, weighed, and frozen in liquid nitrogen (in under 30 s). The go-
nadal adipose depot, kidney, and skeletal muscles (gastrocnemius, tibialis
anterior) were dissected, weighed, and flash-frozen in liquid nitrogen. The
EDL and soleus were dissected, pinned to a circular piece of cork board at
the native muscle length, and flash-frozen in isopentane cooled liquid ni-
trogen. All tissues were subsequently stored at −80 °C until further pro-
cessing. Lung tissue was fixed for 12 h in 4% buffered paraformaldehyde
(Affymetrix) at 4 °C on a shaker, then stored in 70% ethanol at 4 °C.
Serum and Tissue Metabolites. Blood was centrifuged (10,000 × g for 10 min
at 4 °C), and plasma was stored at −20 °C. Plasma β-hydroxybutyrate, TG
(Stanbio Laboratory), NEFA (Wako Life Sciences), lactate (Sigma-Aldrich),
and acetoacetate (Abcam) were determined using commercially available
kits. Serum insulin, IGF1, IL-6, corticosterone (APLCO Diagnostics), and
IGFBP3 (R&D Systems) levels were quantified by ELISA.
For glycogen measurements, liver tissue (30–50 mg) and dilutions of gly-
cogen type III obtained from rabbit liver (Sigma-Aldrich) were homogenized in
0.03 N HCl. An aliquot of the homogenate was mixed with 1.25 N HCl and
heated for 1 h at 95 °C. Samples were centrifuged at 18,400 × g, and 10 μL of
supernatant was mixed with 1 mL of glucose oxidase reagent (Stanbio Labo-
ratory). After a short incubation at 37 °C, the absorbance was read at 505 nm.
Metaboliteswere extracted from liver (30–50mg) and gastrocnemius (whole
muscle) using 80% methanol (69). Targeted LC/MS analyses were performed
on a Q Exactive Orbitrap mass spectrometer (Thermo Scientific) coupled to a
Vanquish UPLC system (Thermo Scientific). The Q Exactive operated in polarity-
switching mode. A Sequant ZIC-HILIC column (2.1 mm i.d. × 150 mm, Merck)
was used for separation of metabolites. Flow rate was 150 μL/min. Buffers
consisted of 100% acetonitrile for A, and 0.1% NH4OH/20 mM CH3COONH4 in
water for B. Gradient ran from 85 to 30% A in 20 min followed by a wash with
30% A and reequilibration at 85% A. Metabolites were identified on the basis
of exact mass within 5 ppm and standard retention times. Relative metabolite
quantitation was performed based on peak area for each metabolite. All data
analyses were done using scripts written in house.
RNA Seq and qPCR. Total RNA was extracted from liver (30–50 mg) and gas-
trocnemius (whole muscle) using TRIzol (Thermo Fisher) followed by clean-up
using RNeasy kit (Qiagen). One microgram of total RNA of each sample was
submitted to the WCM Genomics Resources Core Facility. Raw sequenced reads
were aligned to the mouse reference GRCm38 using STAR (v2.4.1d, 2-pass mode)
aligner. Aligned reads were quantified using Cufflinks (v2.2.1) to obtain frag-
ments per kilobase per million (FPKM) and raw counts using HTSeq (v0.6.1) (70,
71). The computational pipelines were managed with Nextflow (72). Statistical
analyses on the normalized expression values (FPKM) were performed using the
Qlucore Omics Explorer 3.0 software (Qlucore). The identification of significantly
differential variables between the subgroups of mRNA expression was per-
formed using DESeq2 (v1.14.1), and variables with adjusted P values below
0.05 and log-transformed fold-change greater than 1 were considered significant.
Differentially expressed gene symbols were imported into DAVID functional an-
notation tool (https://david.ncifcrf.gov/summary.jsp) to identify signifi-
cantly enriched KEGG pathways. Hierarchical cluster analysis of differentially
expressed mRNA was performed using the Qlucore Omics explorer. These data
were uploaded to the Gene Expression Omnibus repository (GSE107470).
For qPCR, cDNA was synthesized from total RNA extracted above using
SuperScript VILO Master Mix (Thermo Fisher). cDNA was amplified using the
Applied Biosystems TaqMan Gene Expression Assays (Thermo Fisher) with the
following primers: Acadm (Mm01323360_g1), Acox1 (Mm01246834_m1), Actb
(Mm00607939_s1), Bdh1 (Mm00558330_m1), Cpt1a (Mm01231183_m1), Cyp4a14
(Mm00484135_m1),Ddit4 (Mm00512504_g1), Ehhadh (Mm00619685_m1),Hmgcs2
(Mm00550050_m1), Pik3ca (Mm00435673_m1), Pik3r1 (Mm01282781_m1), Sesn1
(Mm01185732_m1).
Histology. Lung tissues were fixed with 4% paraformaldehyde solution in PBS
(Affimetrix) and were embedded into paraffin. Three-micrometer sections
were cut for staining with H&E, elastica-van-gieson and Alcian blue–perodic
acid Schiff (PAS). Tumor subtypes and surface area for invasive and in situ
components were assessed by a blinded pathologist. In situ cancer areas
were confirmed by using elastica-van-gieson staining. For goblet cells to
confirm the mucinous subtype, we used Alcian blue–PAS staining.
For EDL and soleus fiber analysis, serial frozen sections (8 μm) were cut at
midbelly of the muscles using a cryostat at −21 °C and placed onto glass
slides (Superfrost/Plus; Fisher Scientific). Single-fiber CSA and distribution
were determined in images from tissue sections immunostained for laminin,
as previously described (73). Photomicrographs were taken and morphom-
etric measurements were made with Photoshop CS3 (Adobe) using a 0.3 μm
per pixel scale. Fiber data for all animals in each group were merged to
create a histogram or summarized by mean and SE using Prism 6 (GraphPad).
Type I, IIa, IIx, and IIb fibers were distinguished through immunohisto-
chemistry as previously described (74) and quantified in Photoshop.
Western Blots and Antibodies. Liver (50–70 mg) and tibialis anterior (whole
muscle) were lysed using lysis buffer containing 50 mM Tris·HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Nonidet P-40, 0.5% Triton
X-100, and 1 tablet (per 10 mL) of protease and phosphatase inhibitor. Protein
extracts (50 μg) were separated by 4–12% NuPAGE Bis-Tris gel (Invitrogen)
and transferred to 0.45-μm PVDF membranes with wet transfer cells (Bio-Rad
Laboratories). After 1 h of blocking with Tris-buffered saline with 0.1% (vol/vol)
Tween 20 containing 5% (wt/vol) BSA, membranes were incubated overnight at
4 °C with antibodies against ACOX1 (ab184032), HMGCS2 (ab137043), BDH1
(Proteintech 15417–1-AP), p110α (BD 611399), p85 (CST 4292), Ser473 AKT (CST
4058), AKT (CST 9272), Ser2448 mTOR (CST 5536), mTOR (CST 2983), Ser792
Raptor (CST 2083), Raptor (CST 2280), Ser235/6 S6 (CST 2211), S6 (CST 2217),
Ser757 ULK1 (CST 6888), Ser555 ULK1 (CST 5869), ULK1 (Sigma 7481), Thr37/46
4E-BP1 (CST 2855), 4E-BP1 (CST 9452), Ser79 ACC (CST 3661), ACC (CST 3676),
Thr175 AMPK (CST 2535), AMPK (CST 2532), acetyl-Histone H3 (Lys9/Lys14) (CST
9677), GAPDH (Proteintech 10494-1-AP), and β-actin (ab8227) at a 1:1,000
dilution in 5% BSA followed by a TBST wash and the appropriate secondary
antibody (1:3,000) for 1 h at room temperature. The signals were detected on
HyBlot CL Autoradiography Film (Denville Scientific) with SuperSignal Western
Blot enhancer solution (Thermo Fisher), scanned at 600 dpi resolution, cropped
with Photoshop CS3 (Adobe), and quantified using ImageJ software version
1.49v (NIH).
For PPARα immunoprecipitation, hepatic nucleic, and cytoplasm extracts
were separated using NE-PER reagents (Thermo Fisher). Nuclear (200 μg) and
cytoplasm (500 μg) protein lysates were precleared with control agarose resin
and IgG, and then incubated overnight with 25 μg of agarose-conjugated PPAR
alpha antibody (sc-398394 AC). Input (30 μg) and immunoprecipitation protein
samples were mixed in NuPAGE 4× LDS buffer (Invitrogen) and separated using
a 7.5% Tris-Glycine gel and transferred to a PVDF membrane as above. For
PPARα detection, a polyclonal antibody was used (Thermo PA1822A).
Statistics. Data are expressed as means ± SEM. Statistical analyses for all data
were performed by Student’s t test using Prism 6 (GraphPad) or Excel 2013
(Microsoft). Statistical significance is indicated in figures using the following
denotation: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Study Approval. All animal care and treatments were carried out in compli-
ance with Weill Cornell Medical College Institutional Animal Care and Use
Committee guidelines.
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